Guidelines, Multiple sclerosis, Therapy, RecommendationsThe management and treatment of multiple sclerosis (MS) is becoming more and more complex as many medications are now avail- able, with different routes of administration, mechanisms of action, and effectiveness and safety profiles. The decision-...
New updates to the American Academy of Neurology (AAN) guidelines on immunization and multiple sclerosis (MS) outline recommendations for patients with the disease to receive their vaccinations. The guideline, which updates the 2002 AAN guideline, is based on a systematic review of evidence...
INSIDE THE AAN SECTIONS: The Multiple Sclerosis Section — Navigating Escalating Costs and New Treatment FrontiersAn abstract is unavailable.doi:10.1097/01.NT.0000461965.69190.f3Hiscott, RebeccaNeurology Today
Multiple Sclerosis Disease modifying treatment National guideline United Arab Emirates Middle East Gulf UAE 1. Introduction The United Arab Emirates (UAE) is home to about 10 million people, of which one million are Emirati citizens. UAE is considered a country with medium prevalence for Multiple ...
Available from: URL: http://www.abstracts2view.com/aan Frenay CL, Debouverie M, Brassat D, Vermersch P, Defer G, de Seze J, Clavelou P, Heinzlef O, Rumbach L, Wiertlevski S, Tourniaire P, Berthier F.Cancer Risk among Patients with Multiple Sclerosis during the Treatment Era: ...
Treatment of multiple sclerosis (MS) has 2 aspects: immunomodulatory therapy (IMT) for the underlying immune disorder and therapies to relieve or modify symptoms. IMT is directed toward reducing the frequency of relapses and slowing progression. Currently, most disease-modifying agents have been appro...
Learn more about clinical recognition, workup, and optimal treatment of multiple sclerosis, as well as how to rule out other neurologic conditions with similar presentations.
AAN 2024: Exploring New Horizons in RRMS Treatment Dr Sy reflects on the 2024 AAN Annual Meeting, delving into the evolving landscape of RRMS management. He emphasizes the importance of nuanced treatment approaches amid growing concerns over the long-term safety of B-cell depletion therapy. Additio...
#AAN2022 – Tolebrutinib Reduces Brain Damage Up to 1.5 Years in Trial Long-term treatment with tolebrutinib significantly reduced signs of disease-related brain damage in people with relapsing multiple sclerosis (MS), according to new data from a Phase 2 clinical trial and its extension study...
Multiple sclerosis (MS) is an early-onset immune-mediated neuroinflammatory disease that leads to progressive neurodegeneration and a wide spectrum of disorders in functional systems [1]. The prevalence has increased substantially in many regions since 1990, reaching approximately 2.8 million persons with...